Enovis (ENOV) and Its Peers Head to Head Analysis

Enovis (NYSE:ENOV) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its rivals? We will compare Enovis to related businesses based on the strength of its institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.

Earnings & Valuation

This table compares Enovis and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Enovis	$2.25 billion	-$1.18 billion	-3.01
Enovis Competitors	$1.87 billion	$137.20 million	5.88

Enovis has higher revenue, but lower earnings than its rivals. Enovis is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider and Institutional Ownership

98.5% of Enovis shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 2.9% of Enovis shares are owned by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

Enovis has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Enovis’ rivals have a beta of 2.68, meaning that their average share price is 168% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Enovis and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1	1	10	0	2.75
Enovis Competitors	4295	10588	18373	832	2.46

Enovis presently has a consensus price target of $38.62, suggesting a potential upside of 39.22%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.04%. Given Enovis’ stronger consensus rating and higher possible upside, research analysts plainly believe Enovis is more favorable than its rivals.

Profitability

This table compares Enovis and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enovis	-22.86%	13.23%	5.19%
Enovis Competitors	-303.57%	-175.14%	-22.20%

Summary

Enovis beats its rivals on 8 of the 13 factors compared.

Enovis Company Profile

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.